Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
TL118
i
Other names:
TL118
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Teligene
Drug class:
Trk inhibitor
Related drugs:
‹
repotrectinib (27)
SIM1803-1A (5)
FCN-098 (3)
K-252a (1)
BAY 2731954 (1)
AGX87 (0)
ONO-7579 (0)
TY-2136b (0)
VC004 (0)
XZP-5955 (0)
TSR-011 (0)
repotrectinib (27)
SIM1803-1A (5)
FCN-098 (3)
K-252a (1)
BAY 2731954 (1)
AGX87 (0)
ONO-7579 (0)
TY-2136b (0)
VC004 (0)
XZP-5955 (0)
TSR-011 (0)
›
Associations
News
Trials
Filter by
Latest
1m
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients (clinicaltrials.gov)
P2, N=60, Not yet recruiting, Teligene US | Initiation date: Jan 2024 --> May 2024
1 month ago
Trial initiation date
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
|
NTRK1 fusion • NTRK3 fusion • NTRK2 fusion
|
TL118
9ms
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients (clinicaltrials.gov)
P2, N=60, Not yet recruiting, Teligene US
9 months ago
New P2 trial
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
|
NTRK1 fusion • NTRK3 fusion • NTRK2 fusion
|
TL118
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login